WEN-JEN HWU to Ipilimumab
This is a "connection" page, showing publications WEN-JEN HWU has written about Ipilimumab.
Connection Strength
1.262
-
High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients. Melanoma Res. 2017 02; 27(1):24-31.
Score: 0.421
-
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. Clin Cancer Res. 2020 10 01; 26(19):5086-5091.
Score: 0.133
-
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654.
Score: 0.118
-
Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern. J Cutan Pathol. 2018 Jul; 45(7):504-507.
Score: 0.115
-
A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma. Cancer Immunol Immunother. 2017 Oct; 66(10):1359-1366.
Score: 0.108
-
Ipilimumab in the treatment of advanced melanoma - a clinical update. Expert Opin Biol Ther. 2014 Nov; 14(11):1709-18.
Score: 0.089
-
Ipilimumab in the treatment of melanoma. Expert Opin Biol Ther. 2012 Jun; 12(6):773-82.
Score: 0.075
-
Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol. 2011 Dec; 197(6):W992-W1000.
Score: 0.074
-
Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. Clin Cancer Res. 2018 04 15; 24(8):1805-1815.
Score: 0.028
-
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncol. 2017 09; 18(9):1202-1210.
Score: 0.027
-
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017 Feb; 44(2):158-176.
Score: 0.026
-
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA. 2016 Apr 19; 315(15):1600-9.
Score: 0.025
-
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014 Sep 20; 384(9948):1109-17.
Score: 0.022